Xilio Therapeutics, Inc. (XLO) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Xilio Therapeutics reported revenue of $43.8M, up 589.9% from $6.3M the year before. Net income was -$35.0M (a -80.1% net margin), or -$4.19 per diluted share. Operating margin was -95.9%. Operating activities generated -$5.0M of cash, leaving -$5.5M of free cash flow. At fiscal year end, Xilio Therapeutics held $154.7M in total assets against $119.4M in total liabilities, including $137.5M of cash and equivalents.
Open the full interactive Xilio Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Xilio Therapeutics Key Stats
| Share Price | $9.22 |
|---|---|
| Market Cap | $178.9M |
| Revenue YoY Growth | +589.9% |
| 52-Week Range | $7.14 – $11.90 |
| Shares Outstanding | 19.4 million (basic, 2026 Q2) |
Xilio Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6.3M | $43.8M |
| Operating Income | -$75.0M | -$89.1M | -$79.1M | -$60.6M | -$42.0M |
| Pre-Tax Income | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M |
| Income Tax | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M |
| Diluted EPS | -$189.28 | -$45.08 | -$38.92 | -$15.26 | -$4.19 |
Xilio Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $19.1M | $13.7M | $12.6M | $18.7M |
| Net Income | -$16.3M | $10.4M | -$9.5M | -$6.4M |
| Diluted EPS | -$1.54 | — | -$0.58 | -$0.33 |
Xilio Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $198.1M | $120.4M | $44.7M | $55.3M | $137.5M |
| Current Assets | $202.5M | $124.5M | $48.1M | $60.2M | $145.0M |
| Total Assets | $218.1M | $139.2M | $60.9M | $71.1M | $154.7M |
| Current Liabilities | $12.8M | $21.1M | $16.0M | $27.3M | $56.3M |
| Total Long-Term Debt | $9.6M | $9.8M | — | — | — |
| Total Liabilities | $32.6M | $33.5M | $24.1M | $53.5M | $119.4M |
| Shareholders' Equity | $185.4M | $105.6M | $36.8M | $17.6M | $35.3M |
Xilio Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$80.8M | -$75.7M | -$68.6M | -$18.4M | -$5.0M |
| Cash From Investing | -$1.1M | -$1.9M | -$486,000 | -$36,000 | -$518,000 |
| Cash From Financing | $260.7M | -$69,000 | -$6.5M | $29.2M | $87.8M |
| Free Cash Flow | -$81.9M | -$77.6M | -$69.1M | -$18.4M | -$5.5M |
Figures from Xilio Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Xilio Therapeutics financials page for every line item.
Xilio Therapeutics Company Profile
| Ticker | XLO |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001840233 |
Frequently Asked Questions
What was Xilio Therapeutics' revenue in fiscal 2025?
Xilio Therapeutics (XLO) reported revenue of $43.8M for fiscal 2025.
What is Xilio Therapeutics' annual revenue history?
Xilio Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $6.3M; 2025: $43.8M.
What was Xilio Therapeutics' net income in fiscal 2025?
Xilio Therapeutics reported net income of -$35.0M for fiscal 2025.
What was Xilio Therapeutics' earnings per share (EPS) in fiscal 2025?
Xilio Therapeutics' diluted EPS was -$4.19 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Xilio Therapeutics generate in fiscal 2025?
Xilio Therapeutics generated -$5.5M of free cash flow in fiscal 2025.
What was Xilio Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Xilio Therapeutics reported revenue of $18.7M.
How many shares of Xilio Therapeutics are outstanding?
Xilio Therapeutics reported a weighted average of 19.4 million basic shares outstanding in 2026 Q2.
What is Xilio Therapeutics' market cap?
Based on its latest closing price, Xilio Therapeutics (XLO) has a market capitalization of about $178.9M.
When does Xilio Therapeutics' fiscal year end?
Xilio Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Xilio Therapeutics headquartered?
Xilio Therapeutics lists its business address in Waltham, Massachusetts in its SEC filings.